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Abstract
Background: Cathepsin C (Cat C) functions as a central coordinator for activation of many serine proteases in
inflammatory cells. It has been recognized that Cat C is responsible for neutrophil recruitment and production of
chemokines and cytokines in many inflammatory diseases. However, Cat C expression and its functional role in the
brain under normal conditions or in neuroinflammatory processes remain unclear. Our previous study showed that
Cat C promoted the progress of brain demyelination in cuprizone-treated mice. The present study further
investigated the Cat C expression and activity in lipopolysaccharide (LPS)-induced neuroinflammation in vivo and
in vitro.
Methods: C57BL/6 J mice were intraperitoneally injected with either 0.9% saline or lipopolysaccharide (LPS, 5 mg/
kg). Immunohistochemistry (IHC) and in situ hybridization (ISH) were used to analyze microglial activation, TNF-α, IL-
1β, IL-6, iNOS mRNAs expressions and cellular localization of Cat C in the brain. Nitrite assay was used to examine
microglial activation in vitro; RT-PCR and ELISA were used to determine the expression and release of Cat C. Cat C
activity was analyzed by cellular Cat C assay kit. Data were evaluated for statistical significance with paired t test.
Results: Cat C was predominantly expressed in hippocampal CA2 neurons in C57BL/6 J mice under normal
conditions. Six hours after LPS injection, Cat C expression was detected in cerebral cortical neurons; whereas,
twenty-four hours later, Cat C expression was captured in activated microglial cells throughout the entire brain. The
duration of induced Cat C expression in neurons and in microglial cells was ten days and three days, respectively. In
vitro, LPS, IL-1β and IL-6 treatments increased microglial Cat C expression in a dose-dependent manner and
upregulated Cat C secretion and its activity.
Conclusions: Taken together, these data indicate that LPS and proinflammatory cytokines IL-1β, IL-6 induce the
expression, release and upregulate enzymatic activity of Cat C in microglial cells. Further investigation is required to
determine the functional role of Cat C in the progression of neuroinflammation, which may have implications for
therapeutics for the prevention of neuroinflammation-involved neurological disorders in the future.
Keywords: Cathepsin C, Microglia, Lipopolysaccharide, Neuroinflammation
* Correspondence: ma_jianmei@hotmail.com
1Department of Anatomy, Dalian Medical University, No. 9, West Segment of
South Lvshun Road, Dalian, Liaoning 116044, China
Full list of author information is available at the end of the article
© 2012 Fan et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any
medium, provided the original work is properly cited.
Fan et al. Journal of Neuroinflammation 2012, 9:96 JOURNAL OF 
NEUROINFLAMMATIONhttp://www.jneuroinflammation.com/content/9/1/96
Background
Neuroinflammation is associated with many neurodegen-
erative diseases, including Alzheimer’s disease, Parkin-
son’s disease, amyotrophic lateral sclerosis, and multiple
sclerosis. The ubiquitous pathological changes of neu-
roinflammation in these diseases include overactivation
of glial cells, increased proinflammatory cytokine con-
centration, increased blood–brain barrier (BBB) perme-
ability, and leukocyte invasion [1-3]. Numerous reports
have demonstrated that neuroinflammation contributes
to the causation and aggravation of neurodegenerative
diseases [4-6]. The inflammatory mediators, such as
interleukin-1β (IL-1β), interleukin-6 (IL-6), tumor necro-
sis factor-α (TNF-α), chemokines and oxygen free radi-
cals are assumed to stimulate signaling pathways in a
pathological cascade to result in neurodegenerative dis-
eases [7-14].
Cathepsins, a large group of lysosomal proteases, have
been found to participate in the neuroinflammatory pro-
cesses [15-21]. According to their catalytic mechanism,
they are further defined as cysteine (cathepsin B, C, H, L,
S, Z, and so on), aspartic (cathepsin D, and so on) and
serine proteases (cathepsin G, and so on) [22]. The cyst-
eine cathepsins representing the major group of these
enzymes are synthesized as inactive preproenzymes
[23,24]. During the passage to the endoplasmic
reticulum, the prepeptide is removed and the procathep-
sin undergoes proteolytic processing to the mature en-
zyme in the lysosomal compartment. Besides their
physiological roles in cellular protein metabolism, some
cysteine cathepsins are involved in several pathological
processes, especially in the neuroinflammatory processes
of neurodegenerative diseases represented by a tissue-
and cell-specific expression pattern [25-29].
Cathepsin C (Cat C, or dipeptidyl peptidase I, DPPI),
which belongs to cysteine cathepsins with a molecular
mass of about 200 kDa, has been found constitutively
expressed in a variety of tissues in mammals with the
highest levels in lungs, kidneys, liver and spleen, but rela-
tively low in the brain [30-34]. Cat C functions as a key
enzyme in the activation of granule serine proteases in
cytotoxic T lymphocytes, natural killer cells (granzymes
A and B), mast cells (chymase and tryptase) and neutro-
phils (cathepsin G, proteinase 3, and elastase) [35-37].
The roles of Cat C and the activated serine proteases in
modulating the inflammatory responses have been
assessed in a number of inflammation models. For in-
stance, Cat C knockout mice are completely resistant to
the acute arthritis induced by anti-type II collagen anti-
bodies and showed a high degree of protection in a colla-
gen-induced rheumatoid arthritis model [38,39]. In
addition, the inflammatory cells infiltration and inflam-
matory cytokines production have been shown to be
decreased in Cat C knockout mouse models of asthma,
chronic obstructive pulmonary disease (COPD), sepsis
and abdominal aortic aneurysms [40-43]. Based on these
studies, we hypothesized that Cat C in the central ner-
vous system (CNS) might play a similar role in neuroin-
flammation. In this regard, we have found that Cat C
promoted the brain demyelination in cuprizone-treated
mice in our preliminary study (unpublished data). Until
now, the Cat C expression has been studied only on the
mRNA level in the homogenized brain tissue [32-34], the
expression pattern and cellular localization of Cat C in
the brain, as well as the functional role of Cat C in neu-
roinflammation still remain unclear.
In this study, we examined the expression pattern and
cellular localization of Cat C in the brain in lipopolysac-
charide (LPS)-induced neuroinflammation. We further
investigated the expression, release and enzymatic activ-
ity of microglial Cat C in response to LPS and proinflam-
matory cytokines IL-1β, IL-6 stimulations. We found the
brain Cat C expression was markedly enhanced in LPS-
induced neuroinflammation, and LPS and proinflamma-
tory cytokines could induce the expression, release and




Eight-week-old C57BL/6 J mice weighing 25 to 30 g were
used in the experiments. Animals were housed in groups
of five per cage in a 22 ± 2°C and 45~ 65% relative hu-
midity environment under a normal light cycle room
(12-h light/12-h dark; 8:00 a.m. light on ~ 8:00 p.m. light
off ). All animals had free access to food and water. All
procedures were in accordance with the Dalian Medical
University guidelines for the proper care and use of la-
boratory animals and were approved by the Laboratory
Animal Care and Use Committee of Dalian Medical
University.
Lipopolysaccharide-induced treatment
LPS (Escherichia coli, serotype 055:B5, Sigma-Aldrich
Chemical Corp., St. Louis, MO. USA) was used to induce
an inflammatory response. LPS was injected intraperito-
neally at a dose of 5 mg/kg dissolved in sterile, endo-
toxin-free 0.9% saline vehicle. Control injections were
equivolume vehicle. The dosage of LPS was based on a
previous study of LPS-induced neurotoxicity [44].
Tissue preparation
At the time points of one hour, six hours, twelve hours,
twenty-four hours, forty-eight hours, seventy-two hours,
seven days and ten days after LPS injection, mice were
anesthetized with diethyl ether and perfused with 4%
paraformaldehyde solution. The brains were removed
and postfixed with the same fixative overnight. Brains
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were then cryoprotected overnight in phosphate buffered
saline (PBS) containing 20% sucrose, embedded in opti-
mal cutting temperature (OCT) compound (McCormick
Scientific, St. Louis, MO, USA), and serial 18 μm sagittal
sections were made with a cryostat (Leica CM 3050 S,
Leica Microsystems AG, Wetzlar, Germany) and used for
the immunohistochemical (IHC) and in situ
hybridization (ISH) studies.
In situ hybridization
In situ hybridization (ISH) was performed as described
previously [45]. We used digoxigenin (DIG)-labeled Cat
C (NM_009982, 193-1324 bp), IL-1β (NM_008361, 423-
880 bp), TNF-α (NM_013693.2, 575-1607 bp) and indu-
cible nitrite oxide synthase (iNOS) (NM_010927.3, 1921-
2827 bp) cRNA probes. After hybridization of antisense
cRNA probes, samples were incubated overnight with al-
kaline phosphatase-conjugated anti-DIG antibody
(Roche, Basel, Switzerland) at 4°C. Color development
was achieved by incubation with 4-nitro blue tetrazolium
chloride/5-bromo-4-chloro-3-indolyl-phosphate (NBT/
BCIP) for sixteen hours at room temperature. Some sec-
tions were counterstained with Nuclear Fast Red for ob-
servation and analysis. Others were processed for ionized
calcium binding adapter molecule 1 (Iba-1) immunohis-
tochemistry (IHC) after ISH. Images were captured using
the Nikon digital camera system (DS-Fi1, Nikon Corp.,
Tokyo, Japan) in combination with microscopy (Nikon
Eclipse 80i). The number of cells expressing IL-1β, iNOS
mRNAs was counted with use of imageJ 1.41 (National
Institutes of Health). Three sections from each mouse
(with five mice per condition) were used for analysis.
Immunohistochemical staining
IHC was performed as described by Ma et al. [46]. The
following antibodies were used: mouse anti-NeuN mono-
clonal antibody (1:1000, Chemicon, Temecula, CA,
USA), rabbit anti-GFAP polyclonal antibody (1:1000,
Dako, Glostrup, Denmark), rabbit anti-Iba1 polyclonal
antibody (1:500, Wako, Osaka, Japan), goat anti-Cat C
antibody (1:100, R&D Systems, Minneapolis, MN, USA).
Secondary antibodies were labeled with Alexa Fluor 594
(Invitrogen Corp., Carlsbad, CA, USA), Alexa Fluor 488
(Invitrogen) or biotin (1:200, Vector Laboratories Inc.,
Burlingame, CA, USA) antibodies. After IHC reaction,
images were captured using the Nikon digital camera
system (DS-Fi1) in combination with microscopy (Nikon
eclipse 80i).
Cell culture
Primary microglial cells were harvested from primary
mixed glial cell cultures prepared from neonatal C57BL/
6 J mice pups as previously reported [44]. In brief, after
the meninges were carefully removed, the neonatal brain
was dissociated by pipetting. The cell suspension was
plated in 10 cm culture dish at a density of one brain per
two dishes in 10 mL Dulbecco’s modified eagle medium
(DMEM) (Sigma) containing 10% fetal bovine serum
(FBS) (ICN Biomedicals, Aurora, OH, USA). After four-
teen to twenty-one days in vitro, mixed glial cell cultures
were dissociated by trypsinization, and the cell suspen-
sion was seeded on a petri dish and incubated for thirty
minutes in a CO2 incubator. Adherent cells were har-
vested as primary microglial cells. Microglial cells were
reseeded in culture plates. The purity of microglial cells
was approximately 99% as determined by CD11b (rat
monoclonal immunoglobulin G (IgG), clone M1/70,
Abcam Inc., Cambridge, MA, USA) staining.
The immortalized murine microglial cell line BV-2 was
a kind gift from Dr. XF Wu (Dalian Medical University,
China) and were maintained in DMEM supplemented
with 10% FBS, 2 mM glutamine and 100 U/mL penicil-
lin/streptomycin at 37°C in 5% CO2 in a humidified
atmosphere.
Nitrite assay
Primary microglial cells and BV-2 cells were cultured in
medium without FBS for twenty-four hours at 1.0 × 105
cells/24-well plate, then treated with LPS (10 ng/mL),
IL-1β (0.1 ng/mL) or IL-6 (0.1 ng/mL) for six hours, re-
spectively. After treatment, the nitrite in the culture
medium was measured as an indicator of nitric oxide
(NO) production. An aliquot of the culture medium was
mixed with a volume of Griess reagent (Beyotime Insti-
tute of Biotechnology, Jiangsu, China), and the absorb-
ance at the wavelength 540 nm was determined using a
microplate reader (iMark, Bio-Rad Laboratories, Tokyo,
Japan). Sodium nitrite at the concentrations of 0 to
100 μM was used as a standard to assess nitrite
concentrations.
Enzyme-linked immunosorbent assay (ELISA)
Primary microglial cells and BV-2 cells were cultured in
the same condition as above, prior to treatment with
various concentrations of LPS (10, 50, 100 ng/mL), IL-1β
(0.1, 1, 10 ng/mL), IL-6 (0.1, 1, 10 ng/mL) for six hours,
respectively. After treatment, mouse Cat C ELISA kit
(R&D) was used for the quantitative measurement of Cat
C in the cell lysates and culture medium.
Semi-quantitative reverse transcription polymerase Chain
reaction (RT-PCR) analysis
The treatment of BV-2 cells was the same as that in
ELISA. After treatment, total RNA from cells was
extracted using Trizol reagent (Invitrogen) according to
the manufacturer’s protocol. Reverse transcription was
performed using SuperScript II Reverse Transcriptase
(Invitrogen). Primers sequences: Cat C: forward: 5’
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CAGAGGCCACACAGCTATCA 3’, reverse: 5’ GCAT-
GATTTGTCAGCTCGAA 3’ (891 bp); β-actin: forward:
5’ ATCATGTTTGAGACCTTCAACA 3’, reverse: 5’
CATCTCCTGCTCGAAGTCTA 3’ (318 bp). All primers
were synthesized by Takara Biotechnology Co. Ltd.
(Dalian, China). The PCR profile consisted of an initial
melting step of one minute at 95°C, followed by thirty
cycles of thirty seconds at 95°C, fifteen seconds at 56°C
and forty-five seconds at 72°C, and a final elongation
step of one minute at 72°C. PCR products were sepa-
rated by 1.2% agarose gel eletrophoresis. Gels were
stained with ethidium bromide and analyzed under ultra-
violet light. The level of Cat C gene expression was cal-
culated as the gray ratio of PCR product of Cat C over
the internal standard (β-actin). The gray values of PCR
product bands were obtained from a computerized image
analysis using Gel-pro Analyzer version 4.5 software
(Media Cybernetics, Silver Spring, MD, USA).
Cathepsin C enzymatic activity assay
BV-2 cells were cultured in the same condition as above,
and then treated with LPS (10, 50 ng/mL), IL-1β (0.1,
10 ng/mL), IL-6 (0.1, 10 ng/mL) for six hours, respect-
ively. Cat C enzymatic activity in cell lysates and culture
medium was determined by cellular Cat C assay kit
(Genmed Scientifics Inc., Arlington, MA, USA). The pro-
cedures were performed according to manufacturer’s pro-
tocols. All samples (50 μg Cat C protein/well in 96-well
plate) were incubated with the substrate, H-Gly-Phe-p-
Nitroaniline, at 37°C for six hours. The product formed
was detected by measuring the absorbance at the wave-
length 405 nm with microplate reader (iMark, Bio-Rad).
Data were presented as relative folds to untreated control.
Statistical analysis
Data were expressed as mean + standard error of the
mean (SEM) from three independent experiments. All
statistical analyses were performed using the Statistical
Package for Social Sciences (Version 11.5). The data
were evaluated for statistical significance with paired t
test. P< 0.05 was considered statistically significant.
Results
Systemic lipopolysaccharide injection induced the
neuroinflammation
In our study, a single intraperitoneal injection of LPS
(5 mg/kg) did not result in death, but caused apparent
systemic inflammation reflected by a fever and hepa-
tosplenomegaly after LPS injection. To investigate
whether LPS-evoked systemic inflammation affected
the brain, we first examined the behavior of microglial
cells by detection of morphology after systemic admin-
istration of LPS. Iba-1 (ionized calcium binding
adaptor molecule-1) was used as a specific marker for
microglial cells and monocytes. The IHC staining
(Figure 1A and B) showed that compared to control mice
(Figure 1A), Iba-1 positive cells displayed thicker and
shorter processes, markedly enlarged cell bodies at six hours
after LPS injection (Figure 1B). The apparent alterations of
Iba-1 positive cells indicate the sufficient activation of
microglial cells in the brain by systemic LPS injection,
which was present for seven days after LPS injection.
To investigate whether LPS systemic injection causes
inflammatory mediators release in the brain, we next
examined the expressions of proinflammatory cytokines
IL-1β and TNF-α mRNAs in the brain at the different
time points following LPS injection by using ISH. At the
same time, we also examined the level of inducible nitric
oxide synthase (iNOS) mRNA expression, since nitric
oxide (NO) production has been widely regarded as rep-
resentative of inflammatory activation [47,48], and iNOS
is responsible for generating high levels of NO in acti-
vated macrophages/monocytes. We found LPS-induced
expressions of IL-1β, TNF-α mRNAs, as well as iNOS
mRNA were different in temporal and spatial patterns
(Figure 1C to H). At one hour after LPS injection, the
expressions of IL-1β (Figure 1C) and TNF-α mRNAs
(data not shown) appeared in the choroid plexus, the cir-
cumventricular organs, and the leptomeninges. At six
hours, the expressions of these cytokines increased dra-
matically (Figure 1D and G). Peak cytokines were cap-
tured at twelve hours after LPS injection and distributed
throughout the entire brain (Figure 1G). At twenty-four
hours, the expression of L-1β mRNA (Figure 1G) or
TNF-α mRNA (data not shown) decreased significantly
and became barely detectable, compared to the expres-
sion at six hours and twelve hours. While iNOS mRNA
expression started to appear in choroid plexus (Figure 1E)
at twenty-four hours after LPS injection. The iNOS
mRNA expression was detected in the brain parenchyma
(Figure 1F) and throughout the brain at forty-eight hours
and maximized at seventy-two hours. On the seventh
day after LPS injection, iNOS mRNA expression
decreased significantly compared to the expression at
forty-eight hours and seventy-two hours (Figure 1H).
Our data indicate that induced IL-1β and TNF-α
mRNAs were expressed earlier than iNOS mRNA, how-
ever, the iNOS mRNA expression lasted longer than IL-
1β and TNF-α mRNAs after LPS injection. The presence
of highly activated microglial cells and the synthesis of
proinflammatory mediators in the brain demonstrated
that systemic LPS injection indeed induced
neuroinflammation.
Neuroinflammation-induced cathepsin C expression in the
brain
Previous studies have shown that Cat C plays crucial
roles in the processes of peripheral inflammation, but
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the expression pattern of Cat C in the CNS has not been
reported. Thus, first, we examined the expression pattern
of Cat C in control mice by using IHC staining and ISH
staining. We found that Cat C IHC staining was predom-
inantly expressed in the pyramidal neurons of the hippo-
campal CA2 region (Figure 2C to D), the choroid plexus
in ventricles (Figure 2A and C), the leptomeninges (Fig-
ure 2C) and the vascular cells (Figure 2C). A few Cat C-
expressing neurons in the vicinity of the pyramidal
neuron layer in the CA2 region appeared to be
interneurons (Figure 2C). Dense Cat C-labeling granules
scattered in the cytoplasm and processes, sparing the nu-
cleus (Figure 2D). No obvious Cat C labeling was found
in other brain regions. The ISH results showed that the
expression pattern of Cat C mRNA was consistent with
that of Cat C protein (Figure 2A to B). These findings in-
dicate that the Cat C gene is expressed at low level in
the brain under physiological conditions.
Next, we tested Cat C expression in the brain by exam-
ining regional distribution and cellular localization of
Figure 1 Activation of microglial cells and the expression of proinflammatory mediators following LPS injection. Iba-1 IHC staining
showed the processes of microglial cells are ramified in control (A). At six hours after LPS injection the processes of microglial cells became
thicker and shorter, and cell bodies became larger (B). ISH results showed IL-1β mRNA expression appeared in choroid plexus and hippocampal
fimbria at one hour after LPS injection (arrows in C), and occurred extensively in the whole brain at six hours after LPS injection, here is an
example in cerebral cortex (D). iNOS mRNA expression appeared only in choroid plexus at twenty-four hours after LPS injection (arrows in E), and
then developed in the cerebral cortex (F). Quantitative analysis of the number of IL-1β mRNA- (G) and iNOS mRNA- (H) expressing cells in the
cerebral cortex at different time points after LPS injection. *P< 0.05, compared with six hours, twelve hours (G); forty-eight hours, seventy-two
hours (H). Scale bar = 20 μm (A, B, F); 50 μM (C); 50 μM (D, E). n = 5 per condition. Cat C, cathepsin C; Iba-1, ionized calcium binding adaptor
molecule-1; IHC, immunohistochemistry; iNOS, inducible nitric oxide synthase; ISH, in situ hybridization; LPS, lipopolysaccharide.
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Cat C at different time points following LPS injection. At
six hours after LPS injection, in addition to the previ-
ously reported Cat C positive cells in the CA2 region of
the hippocampus under physiological conditions, a large
number of Cat C immunopositive cells with neuronal
morphology were found to distribute evenly in the cere-
bral cortex (Figure 3A). At twenty-four hours after LPS
injection, we detected Cat C immunopositive signals in
the cells with glial morphology in the hippocampus, cor-
tex, substantia nigra (SN), striatum, cerebellum, brain
stem and other brain regions (Figure 3G to I). Thus, we
concluded that LPS injection for twenty-four hours could
induce a global expression of the Cat C immunopositive
signals, presumably in both neuronal and glial cells.
To confirm the phenotype in Cat C immunopositive cells,
we performed double stainings in the following combin-
ation: Cat C (IHC) and NeuN (neuronal marker, IHC); Iba-
1 (microglial cell marker, IHC) following Cat C (ISH); GFAP
(astrocyte marker, IHC) following Cat C (ISH). At six hours
after LPS injection, almost all the Cat C positive cells in the
cortex expressed NeuN (Figure 3A to C), while at twenty-
four hours, the majority of Cat C mRNA positive cells were
colabeled with Iba-1 (Figure 3J and K), but we did not find
colocalization of Cat C mRNA and GFAP (data not shown).
These data indicate that six hours after LPS injection Cat C
expressed in cortical neurons; twenty-four hours after,
microglial cells initiated to express Cat C. We found neur-
onal Cat C expression became faint on the seventh day, un-
detectable on the tenth day after LPS injection (data not
shown). Microglial Cat C expression decreased significantly
and became almost undetectable at seventy-two hours after
LPS injection (data not shown). These observations suggest
that the time course of Cat C expression in neurons and
microglial cells is different.
To determine whether the transcriptional level of the Cat
C gene corresponds to the reported expression of Cat C
protein in the brain, we used ISH to examine the levels of
Cat C mRNA expression at same time points following LPS
injection. ISH results showed alterations in the expression
pattern of Cat C mRNA were similar to those of the Cat C
protein (Figure 3D to F).
Taken together, the data indicate that LPS-induced
neuroinflammation triggered a transient induction of Cat
C expression in neurons and microglial cells with differ-
ential temporal and spatial patterns.
Lipopolysaccharide and proinflammatory cytokines
induced the expression of cathepsin C gene in vitro
In our present study, we systemically administrated a high-
dose LPS (5 mg/kg) to mimic deleterious systemic infec-
tions. LPS administration activated microglial cells, induced
proinflammatory mediators, Cat C mRNA and protein
Figure 2 The expression pattern of Cat C mRNA and protein in the control brain. ISH (A and B) and IHC (C and D) staining were performed
in control mice. The rectangles in A and C which included the CA2 area were enlarged into B and D, respectively. Cat C gene was predominantly
expressed in the CA2 neurons of the hippocampus (B and D), interneurons (dotted arrow in C), choroid plexus (thick solid arrows in A and C),
leptomeninges (open arrow in C) and vascular cells (thin solid arrow in C). Scale bar = 100 μm (A, C); 20 μM (B, D). n = 5 per condition. Cat C,
cathepsin C; IHC, immunohistochemistry; ISH, in situ hybridization.
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expressed in the brain. Apart from that, we also noticed that
peak of IL-1β, IL-6 and TNF-α mRNAs expressions
appeared at twelve hours after LPS injection, while signifi-
cantly higher Cat C expression in microglial cells was
detected at twenty-four hours after LPS injection. This time
difference in expression suggests that proinflammatory
cytokines might induce Cat C expression in microglial cells.
Furthermore, Rao et al. [32] previously reported that the
treatment of lymphocytes with interleukin-2 (IL-2) resulted
in a significant increase in Cat C mRNA levels by Northern
analyses. Therefore, we hypothesized an inducible effect of
proinflammatory cytokines on Cat C expression in the
microglial cells.
To test our hypothesis, we examined the NO concentra-
tion in the culture medium and Cat C protein and mRNA
expression in cell lysates and culture medium of the BV-2
cells or primary microglial cells treated with various con-
centrations of LPS (10, 50, 100 ng/mL), IL-1β (0.1, 1, 10 ng/
mL) or IL-6 (0.1, 1, 10 ng/mL). We first determined the
NO level in the culture medium following treatment with
LPS (10 ng/mL), IL-1β (0.1 ng/mL) or IL-6 (0.1 ng/mL).
There was a significantly higher level of NO in the culture
medium of both BV-2 cells and primary microglial cells
after treatments, compared to untreated cells (P< 0.01)
(data not shown). This indicates that these inflammatory
stimulators successfully activated microglial cells, even at
the lowest concentrations.
Then we examined Cat C protein levels in cell lysates
and culture medium by ELISA. Compared to untreated
cells cultured, Cat C protein expression was increased in
Figure 3 The expression of Cat C was induced in the brain at six hours and twenty-four hours following LPS injection. IHC double
staining showed that the Cat C expression was induced in cortical neurons at six hours after LPS injection (A to C). After LPS injection for twenty-
four hours, the expression of Cat C mRNA and protein was induced further and distributed throughout the entire brain, such as the cortex (D and
G), hippocampus (E and H) and SN (F and I). Double staining of Iba-1 (IHC) and Cat C (ISH) showed that Cat C expression was induced in
microglial cells at twenty-four hours after LPS injection (J and K). Scale bar = 20 μm (A to C, J and K); 50 μm (D to I). n = 5 per condition. Cat C,
cathepsin C; Iba-1, ionized calcium binding adaptor molecule-1; IHC, immunohistochemistry; ISH, in situ hybridization; LPS, lipopolysaccharide. SN,
substantia nigra.
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a dose-dependent manner, in either BV-2 cell lysates or
primary microglial cell lysates, following six-hour LPS
treatment (Figure 4A). Similar results were seen in cell
lysates with IL-1β or IL-6 treatment (Figure 4B and C).
In contrast, the secretion of Cat C in the medium was
affected to various extents (Figure 4D to F).
Next, Cat C mRNA expression in stimulated BV-2 cells
was measured by semi-quantitative RT-PCR, which cor-
responds with Cat C protein increases in microglial cells.
We saw lower Cat C mRNA expression in untreated cells
(Figure 5A), while a significantly higher and dose-
dependent expression was seen in LPS (Figure 5A and
D), IL-1β (Figure 5B and E) or IL-6 (Figure 5C and F)
treated cells, suggesting that the expression of Cat C
gene was subjected to transcriptional regulation.
Taken together, the expression and release of Cat C in
response to LPS, IL-1β and IL-6 stimulation in vitro sup-
port the notion that in the brain, Cat C expression could
also be induced by LPS and proinflammatory cytokines.
Lipopolysaccharide and proinflammatory cytokines
upregulated cathepsin C enzymatic activity in vitro
Cat C functions as a key enzyme in the activation of
granule serine proteases in inflammatory cells. Once
activated, serine proteases will trigger a series of
reactions leading to tissue damage and chronic inflam-
mation. Therefore, it is essential to investigate the altera-
tions of Cat C enzymatic activity in neuroinflammation.
In order to know whether the Cat C induced by LPS and
proinflammatory cytokines has enzymatic activity, we
tested Cat C activity in BV-2 cell lysates and culture
medium following six-hour treatment with LPS (10,
50 ng/mL), IL-1β (0.1, 10 ng/mL), or IL-6 (0.1, 10 ng/
mL). The results showed that LPS (Figure 6A), IL-1β
(Figure 6B) or IL-6 (Figure 6C) significantly upregulated
Cat C enzymatic activity in cell lysates, whereas the in-
crease of Cat C enzymatic activity in the medium was
only detected with LPS treatment (Figure 6A), no signifi-
cant increase of Cat C enzymatic activity was found with
IL-1β or IL-6 treatment (Figure 6B, C).
Discussion
The systemic inflammation may induce neuroinflamma-
tion by producing circulating cytokines, which in return
will have an important impact on the CNS [21,49].
Alterations in brain metabolism and function were
observed in almost 70% of septic patients or in animals
subjected to systemic inflammation or septic shock
[14,50,51]. LPS, a component of the cell wall of gram-
negative bacteria, could stimulate immune cells to
Figure 4 The expression and release of Cat C were induced following LPS, IL-1β and IL-6 treatments in BV-2 cells and primary
microglial cells. The levels of Cat C in cell lysates and culture medium were measured by ELISA. The expression levels of Cat C in lysates of BV-2
cells and primary microglial cells were showed at six hours after treatment with LPS (A, 0 to 100 ng/mL), IL-1β (B, 0 to 10 ng/mL) and IL-6 (C, 0 to
10 ng/mL), respectively. The levels of Cat C in the medium of BV-2 cells and primary microglial cells after the same treatments were showed in D,
E and F, respectively. * or #: P< 0.05, ** or ##: P< 0.01, compared with untreated control. Data were expressed as mean+ SEM from three
independent experiments. Cat C, cathepsin C; ELISA, enzyme-linked immunosorbent assay; LPS, lipopolysaccharide.
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release an array of proinflammatory mediators resulting
in a septic inflammatory response [52-57]. Most effects
by peripherally administered LPS are likely mediated
through LPS receptors outside the BBB. LPS is a macro-
molecule with a molecular weight of approximately 50 to
100 kDa [58], only a minimal amount of LPS is capable
to cross the BBB [59]. The mechanisms by which LPS is
transduced into the CNS and causes neuroinflammation
are not fully understood. Based on our observation and
other studies, we considered the following possibilities:
(1) Circulating LPS might enter the brain parenchyma
through circumventricular organs, choroid plexus and
leptomeninges. These structures which are enriched with
the LPS receptor, CD14 and toll-like receptor 4 (TLR4)
[60], will allow a rapid transcription of proinflammatory
cytokines across the brain parenchyma. We have
consistently observed the expressions of IL-1β, TNF-α in
these structures at one hour after systematic LPS injec-
tion, supporting this possibility. (2) Circulating LPS and
proinflammatory cytokines together act on the brain
microvasculature leading to the transcriptional activation
of a wide range of proinflammatory cytokines and che-
mokines [61], which may cross the BBB to mediate cen-
tral effects. (3) Circulating LPS may enter the brain
directly through opening of the BBB, but only in cases of
brain infections or deleterious systemic infections asso-
ciated with the opening of the BBB. In our present study,
we administrated LPS at a dose of 5 mg/kg, which was
reported to induce serious systemic infection [44]. It has
been reported that astrocytes were severely damaged by
LPS in the SN [62]. Since astrocytes are a structural
component of the BBB, the permeability of the BBB
Figure 5 The expression of Cat C mRNA was induced following LPS, IL-1β and IL-6 treatments in BV-2 cells. The levels of Cat C mRNA
were measured by RT-PCR after treatments of LPS (0 to 100 ng/mL), IL-1β (0 to 10 ng/mL) and IL-6 (0 to 10 ng/mL). The example of PCR product
band and averaged gray ratio at the each of treatments were shown in (A) and (D), (B) and (E), (C) and (F), respectively. Note a dose-dependent
expression of Cat C mRNA was found in three groups of treatments. *: P< 0.05, **: P< 0.01, compared with untreated control. Data were
expressed as mean+ SEM from three independent experiments. Cat C, cathepsin C; LPS, lipopolysaccharide; RT-PCR, reverse transcription
polymerase chain reaction.
Figure 6 Effects of LPS, IL-1β and IL-6 treatments on the Cat C activity in BV-2 cells. The intracellular and extracellular activity of Cat C in
BV-2 cells after six-hour treatment of LPS (10, 50 ng/mL), IL-1β (0.1, 10 ng/mL) and IL-6 (0.1, 10 ng/mL) were measured and showed in (A), (B) and
(C), respectively. * or #: P< 0.05, **: P< 0.01, compared with untreated control. Data were expressed as mean+ SEM from three independent
experiments. Cat C, cathepsin C; LPS, lipopolysaccharide.
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could be increased due to the damaged astrocytes. (4)
The inflammatory cells of the bloodstream activated by
systemically administrated LPS may enter the brain and
cause neuroinflammation.
Much evidence suggests that LPS-induced systemic in-
flammation can activate microglial cells (resident innate
immune cells) and neurons in the brain [34,63,64]. And
the activated microglial cells and neurons could release
cathepsins from their lysosomes, resulting in the neuronal
death and neurodegeneration [15-21]. Cat C is the physio-
logical activator of serine proteases from immune and in-
flammatory cells vital for defense of an organism.
Dominant-negative mutations of human Cat C gene are
linked to the Papillon-Lefèvre syndrome [65], a disease
characterized by early periodontitis, palmoplantar hyper-
keratosis, and a predisposition to bacterial infections. This
indicates that Cat C plays an important role in the im-
mune system. Cat C is differentially expressed in human
tissues. Northern blot analysis showed transcripts of Cat C
were barely detectable in the brain [32-34]. In our study,
ISH and IHC staining revealed the expression of Cat C
mRNA and protein was restricted to the hippocampal
CA2 region, choroid plexus, leptomeninges and vascular
cells in control mice. To the best of our knowledge, it is
the first report of expression pattern of Cat C in the CNS
under physiological conditions. However, the functional
significance of specific Cat C expression pattern in the pyr-
amidal neurons of hippocampus still remains unclear.
In our present study, at six hours after LPS injection, a
substantial Cat C expression was found in cortical neurons,
the expression was present for ten days, but these neurons
did not change the least bit in morphology. These results
indicate that a single LPS injection is not sufficient to cause
obvious damage to neurons. Furthermore, the Cat C mRNA
and protein expressions were detected in microglial cells
throughout the entire brain at twenty-four hours after LPS
injection and were present for up to three days, implying a
differential time-related regulation of Cat C expression in
neurons and microglial cells in the brain in response to sys-
temic immune challenges. Previous studies reported that
several serine proteases expressed in neurons and glial cells,
such as thrombin, trypsin-like serine proteases, are involved
in modulating neuroinflammation and neuroprotection
events in the CNS [66-68]. However, the precise mechan-
isms for activating these enzymes in brain tissue still remain
obscure. Since Cat C is capable of activating many serine
proteases in peripheral tissues, Cat C is likely to be a good
candidate for activating brain serine proteases. In our
present study, we cannot define whether the functional sig-
nificance of an increased Cat C expression in a neuron is a
transiently protective response or a detrimental response to
acute inflammation.
In this study, using cell lines and primary cells, we fur-
ther determined inflammatory factors involved in
induction of microglial Cat C expression and enzymatic
activity. We found the Cat C mRNA and protein expres-
sions in microglial cells were increased dose-dependently
upon various inflammatory stimulations (LPS, IL-1β and
IL-6). Also, these inflammatory mediators increased the
enzymatic activity of Cat C in microglial cells, suggesting
increased Cat C activity could be due to increased
mRNA and protein levels. On the other hand, LPS
caused Cat C activity to increase in the culture medium,
which could be attributed to increased secretion of active
Cat C from microglial cells. Our study suggests regula-
tion of expression, secretion and activity of Cat C in
microglial cells by various inflammatory stimulations
that may be present in vivo under various circumstances,
for example, CNS injury and nerve degeneration [69-71].
Cat C is synthesized as inactive preprocathepsin C in vivo
and is processed into its active mature form by a series of
proteolytic cleavages. Some endopeptidases, presumably
cathepsin L or S, are responsible for the activation of Cat C
[72]. Once activated, Cat C mediates the conversion of
granule serine proteases from their inactive (zymogen) into
the enzymatically active protease by removing an N-ter-
minal propeptide [38]. Cat C plays an immunoregulatory
role through activating serine proteases during inflamma-
tion. The findings in Cat C knockout mice supported the
role of Cat C in modulating inflammatory processes in vivo.
Neutrophils of Cat C knockout mice showed very little en-
zymatic activity of serine proteases and demonstrated a
strongly decreased infiltration to the sites of inflammation
in either an experimental arthritis model or an asthma
model [38,43]. Importantly, this was accompanied by
decreased local production of inflammatory chemokines
(such as CXCL2) and cytokines (such as TNF-α, IL-1β, IL-
6). Based on these studies of Cat C mediating peripheral in-
flammation and our present findings in CNS, we
hypothesize that the functional role of Cat C in LPS-
induced neuroinflammation is as follows: the activated
microglial cells produce proinflammatory cytokines which
may induce Cat C expression and enzymatic activity; Cat C
further modulates cellular events through activating serine
proteases, leading to cytokines amplification. Hence, the
interaction between inflammatory cytokines and Cat C in
the brain may be responsible for the continuous inflamma-
tory cycle in neurodegenerative diseases as well as other
neuroinflammation-involved neurological disorders.
Conclusions
In our current study, we established an animal model of
neuroinflammation by LPS systemic administration. We
presented data showing the regional distribution and cel-
lular localization of Cat C, a lysosomal cysteine protease,
in the brain. Our study demonstrated the alterations of
Cat C in neuroinflammation. We found Cat C was
expressed in the brain at low level under physiological
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conditions. After LPS administration, Cat C expression
was induced in neurons and microglial cells at different
time points. In vitro preparations, stimulations of LPS
and proinflammatory factors IL-1β, IL-6 induced intra-
cellular expression and extracellular release of Cat C as
well as upregulation of enzymatic activity. On the basis
of these results and previous studies showing Cat C
mediated peripheral inflammation, we provided cellular
evidences to support the notion that Cat C could partici-
pate in the development of neuroinflammation in the
CNS. Therefore, further studies of the functional role of
Cat C in the mechanism of neuroinflammation in the
CNS may provide an insight for the therapeutic preven-
tion and/or treatment of neuroinflammation-involved
neurological disorders in the future.
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